Dynavax hat sich als einer der Hauptakteure auf dem Markt für Hepatitis-B-Impfstoffe etabliert, wobei HEPLISAV-B der wichtigste Umsatzträger des Unternehmens ist. Die strategische Ausrichtung des Unte ...

Dynavax Technologies Corporation ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring ...

Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

Am Freitag passte Roy Buchanan, Analyst bei JMP Securities, das Kursziel für Dynavax Technologies (NASDAQ: DVAX) an und erhöhte es von 29,00 auf 33,00 US-Dollar. Die Aktie, die derzeit bei 13,33 US-Do ...

Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Reports Q4 revenue $73.0M, consensus $72.7M. “In 2024, we successfully executed on our strategic growth initiatives, achieving record ...

HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...